Acumen Pharmaceuticals financials
$2.25−2.39%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$32.6M | -$21.1M | -$25.2M | -$26.5M | -$41.8M | -$30.4M | -$39.6M | -$32.3M | -$24.4M | -$17.8M | -$18.5M | -$16.0M |
| Net income | -$32.7M | -$20.7M | -$25.1M | -$26.5M | -$41.0M | -$28.8M | -$37.2M | -$29.8M | -$20.5M | -$14.9M | -$16.5M | -$13.0M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.45 | $-0.33 | $-0.41 | $-0.44 | $-0.68 | $-0.48 | $-0.62 | $-0.50 | $-0.34 | $-0.25 | $-0.28 | $-0.24 |
| EBITDA | -$32.5M | -$21.1M | -$25.2M | -$26.5M | -$41.7M | -$30.4M | -$39.6M | -$32.2M | -$24.4M | -$17.8M | -$18.5M | -$16.0M |
| Operating cash flow | -$18.1M | -$24.1M | -$19.1M | -$30.5M | -$31.8M | -$34.1M | -$27.2M | -$24.6M | -$16.5M | -$17.9M | -$8.3M | -$12.9M |
| Free cash flow | -$18.1M | -$24.1M | -$19.1M | -$30.5M | -$31.8M | -$34.2M | -$27.2M | -$24.6M | -$16.6M | -$17.9M | -$8.3M | -$12.9M |
| Diluted shares | 72.3M | 63.2M | 60.6M | 60.6M | 60.6M | 60.5M | 60.1M | 60.1M | 60.1M | 59.8M | 58.2M | 54.2M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $59.4M | $51.8M | $54.0M | $46.8M | $36.8M | $30.2M |
| Short-term investments | $50.8M | $76.6M | $62.9M | $79.8M | $106.6M | $119.0M |
| Total debt | $31.6M | $31.0M | $31.2M | $30.7M | $29.9M | $29.5M |
| Total assets | $116.0M | $133.6M | $122.8M | $142.2M | $171.9M | $204.5M |
| Total liabilities | $58.7M | $46.2M | $52.4M | $49.0M | $54.8M | $49.0M |
| Shareholders' equity | $57.3M | $87.5M | $70.4M | $93.2M | $117.1M | $155.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology